Market Overview

PFE Q4 Results Preview

Share:

Analyst Eric Lo of Bank of America Merrill Lynch maintains his "buy" rating on Pfizer Inc (NYSE: PFE). The target price for PFE is set to $21.

Pfizer is scheduled to report its Q4 results on February 3. Bank of America Merrill Lynch’s expectations are:

Sales – up 29% to $15.8bn with WYE contributing $3.8bn in sales.

Margins – affected by the acquisition, with gross profit of 81.0% (down -730 bps yoy), SG&A of 28.6% (up +10 bps yoy) and R&D of 17.3% (down -70 bps yoy).

EBIT – up +8% to $5,555mn with margins of 35.1% vs. 41.8% in 4Q:08A.

EPS – upside to estimate of $0.48 (down -27% yoy) mainly from better expense management.

“We believe the current market valuation (8.1x 2011 EPS of $2.30) does not appropriately reflect PFE’s FCF generation capabilities, opportunities to create shareholder value and efforts to diversify its sales mix,” the analysts say.

More Analyst Ratings here

Posted-In: Bank of America Merrill Lynch Eric LoAnalyst Color Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
YAYOAegis CapitalInitiates Coverage On3.3
ASPNCanaccord GenuityReiterates12.0
FFIVCredit SuisseMaintains160.0
UPSUBSMaintains134.0
FFIVRBC CapitalMaintains147.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com